New drug trial aims to shrink tumors before colon cancer surgery
NCT ID NCT06686576
Summary
This study is testing whether a new immunotherapy drug called QL1706, given before surgery, works better than standard treatments for a specific type of colon cancer. It will involve 363 adults with a genetic feature in their tumor (MSI-H/dMMR) that makes it more likely to respond to immunotherapy. The main goals are to see if the drug completely eliminates the tumor before surgery and if it helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.